Simon Cooper
Chief Tech/Sci/R&D Officer at MORPHIC HOLDING, INC.
Net worth: - $ as of 30/03/2024
Simon Cooper active positions
Companies | Position | Start | End |
---|---|---|---|
MORPHIC HOLDING, INC. | Chief Tech/Sci/R&D Officer | 18/03/2024 | - |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 29/02/2024 | - |
Career history of Simon Cooper
Former positions of Simon Cooper
Companies | Position | Start | End |
---|---|---|---|
KEROS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/08/2021 | 11/03/2024 |
KADMON HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 28/02/2021 | 30/06/2021 |
Anokion US, Inc. | Chief Tech/Sci/R&D Officer | 31/12/2018 | 31/01/2021 |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 31/10/2012 | 30/06/2014 |
Sanofi SA | Corporate Officer/Principal | - | - |
Training of Simon Cooper
Newcastle University Medical School | Undergraduate Degree |
Statistics
International
United States | 6 |
Switzerland | 2 |
France | 2 |
Operational
Chief Tech/Sci/R&D Officer | 5 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 7 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
KEROS THERAPEUTICS, INC. | Health Technology |
MORPHIC HOLDING, INC. | Health Technology |
Private companies | 5 |
---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
Sanofi SA | Health Technology |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Health Technology |
Anokion US, Inc. |
- Stock Market
- Insiders
- Simon Cooper
- Experience